RxDoctor Payments Data

Deanna Wallace, NP

Family · Urbana, ILNPI 1609222579

Payments from drug & device makers

$2,958in general payments, 2019–2025

Across 132 payments — averaging $22.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$573
  • Amgen$347
  • Novartis$317
  • AstraZeneca$250
  • E.r. Squibb & Sons, L.L.C.$238
  • Boehringer Ingelheim$215
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$2,89098%
  • Education$682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,958 in reported general payments places this provider in the 85th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$25,157
Medicare patients
215
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$44,070
JardianceEmpagliflozin41$34,088
XareltoRivaroxaban41$32,335
EntrestoSacubitril/Valsartan31$22,528
Metoprolol Succinate59$718
Amiodarone Hcl26$659
Carvedilol51$459
Digoxin12$319
Lisinopril45$302
Potassium Chloride19$297
Torsemide13$285
ClopidogrelClopidogrel Bisulfate19$241
Spironolactone36$238
Ezetimibe12$223
Losartan Potassium31$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$44,07047 claims
Boehringer IngelheimJardiance$215$34,08841 claims
Johnson & JohnsonXarelto$573$32,33541 claims
NovartisEntresto$317$22,52831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,941 family providers in Illinois.

Other family in Urbana

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →